Novavax to Participate in National Vaccine Advisory Committee Meeting

June 17, 2021 |

1 min read

Novavax, Inc. today announced that Gregory M. Glenn , M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services’ National Vaccine Advisory Committee (NVAC).

GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services’ National Vaccine Advisory Committee (NVAC) meeting, taking place virtually on June 17. Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Session details are as follows:

Date:	Thursday, June 17, 2021
Time:	3:15 p.m. – 4:15 p.m. Eastern Time (ET)
Title:	Experiences in the Field: COVID-19 Vaccine Authorization and Beyond
Novavax Participant:	Gregory M. Glenn, M.D., President, Research and Development

For more information or to register for the meeting, visit: https://www.hhs.gov/webforms/nvac/index.html.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com